eMedicine Specialties > Pediatrics: Genetics and Metabolic Disease > Metabolic Diseases
Glycogen-Storage Disease Type II: Follow-up
Updated: Oct 7, 2009
Follow-up
Further Outpatient Care
- Counsel the parents of children with glycogen-storage disease type II (GSDII) regarding the 25% recurrence risk for each subsequent pregnancy, and provide options for prenatal diagnosis.9
- Chorionic villus sampling and amniocentesis both can be used to determine enzyme activity in a fetus.
- Prenatal diagnoses as early as 10 weeks' gestation are reported.
- Emphasize the genetic basis to family members, and encourage communication within the family in order to identify additional carriers.
Complications
- The major complication among infant patients is aspiration pneumonia.
Miscellaneous
Medicolegal Pitfalls
- Failure to counsel parents of children with glycogen-storage disease type II (GSDII) in regard to the 25% recurrence risk with each subsequent pregnancy
Special Concerns
- Successful pregnancy in a woman with the adult form of glycogen-storage disease type II (GSDII) has been reported.
More on Glycogen-Storage Disease Type II |
| Overview: Glycogen-Storage Disease Type II |
| Differential Diagnoses & Workup: Glycogen-Storage Disease Type II |
| Treatment & Medication: Glycogen-Storage Disease Type II |
Follow-up: Glycogen-Storage Disease Type II |
| Multimedia: Glycogen-Storage Disease Type II |
| References |
| « Previous Page | Next Page » |
References
Ausems MG, Verbiest J, Hermans MP, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet. Sep 1999;7(6):713-6. [Medline].
Miyamoto Y, Etoh Y, Joh R, et al. Adult-onset acid maltase deficiency in siblings. Acta Pathol Jpn. Nov 1985;35(6):1533-42. [Medline].
Bulkley BH, Hutchins GM. Pompe's disease presenting as hypertrophic myocardiopathy with Wolff-Parkinson-White syndrome. Am Heart J. Aug 1978;96(2):246-52. [Medline].
Kroos MA, Pomponio RJ, Hagemans ML, et al. Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype. Neurology. Jan 9 2007;68(2):110-5. [Medline].
van der Beek NA, Soliman OI, van Capelle CI, Geleijnse ML, Vletter WB, Kroos MA, et al. Cardiac evaluation in children and adults with Pompe disease sharing the common c.-32-13T>G genotype rarely reveals abnormalities. J Neurol Sci. Dec 15 2008;275(1-2):46-50. [Medline].
Kishnani PS, Corzo D, Leslie ND, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. Sep 2009;66(3):329-35. [Medline].
Nicolino M, Byrne B, Wraith JE, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med. Mar 2009;11(3):210-9. [Medline].
Merk T, Wibmer T, Schumann C, Krüger S. Glycogen storage disease type II (Pompe disease)--influence of enzyme replacement therapy in adults. Eur J Neurol. Feb 2009;16(2):274-7. [Medline].
[Guideline] Cunniff C. Prenatal screening and diagnosis for pediatricians. Pediatrics. Sep 2004;114(3):889-94. [Medline].
Ausems MG, Lochman P, van Diggelen OP, et al. A diagnostic protocol for adult-onset glycogen storage disease type II. Neurology. Mar 10 1999;52(4):851-3. [Medline].
Clinical Trials. A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease. clinicaltrials.gov. Available at http://clinicaltrials.gov/ct/show/NCT00515398?order=2. Accessed 2007.
Engel AG, Gomez MR, Seybold ME, Lambert EH. The spectrum and diagnosis of acid maltase deficiency. Neurology. Jan 1973;23(1):95-106. [Medline].
Engel AG, Hirschhorn R. Acid maltase deficiency. In: Engel AG, Franzine-Armstrong C, eds. Myology: Basic and Clinical. New York, NY: McGraw-Hill; 1996:1533-53.
Hirschhorn R. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL, Sly W, Valle E, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 1995:2443-64.
Hirschhorn R, Reuser AJJ. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL,et, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. 2001;3389-3420.
Isaacs H, Savage N, Badenhorst M, Whistler T. Acid maltase deficiency: a case study and review of the pathophysiological changes and proposed therapeutic measures. J Neurol Neurosurg Psychiatry. Sep 1986;49(9):1011-8. [Medline].
Umapathysivam K, Hopwood JJ, Meikle PJ. Determination of acid alpha-glucosidase activity in blood spots as a diagnostic test for Pompe disease. Clin Chem. Aug 2001;47(8):1378-83. [Medline].
Van der Beek NA, Hagemans ML, Reuser AJ, Hop WC, Van der Ploeg AT, Van Doorn PA, et al. Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord. Feb 2009;19(2):113-7. [Medline].
Further Reading
Keywords
GSDII, Pompe disease, Pompe's disease, acid maltase deficiency, AMD, alpha-1, 4 glucosidase deficiency, glucosidase acid alpha deficiency, GAA deficiency, cardiac form of generalized glycogenosis, glycogen-storage disease type II, type 2 glycogenosis, idiopathic hypertrophic cardiomyopathy, hypoglycemia, cardiomegaly, basilar artery aneurysm, sleep apnea, hypotonia, Wolff-Parkinson-White syndrome, macroglossia, hepatomegaly, enlargement of the heart, isolated left ventricle thickening, biventricular thickening, outflow obstruction, treatment, diagnosis
Follow-up: Glycogen-Storage Disease Type II